{
    "2018-04-30": [
        [
            {
                "time": "2018-01-02",
                "original_text": "FDA Oks Tafinlar + Mekinist For Adjuvant Treatment Of BRAF V600-mutant Melanoma",
                "features": {
                    "keywords": [
                        "FDA",
                        "Tafinlar",
                        "Mekinist",
                        "Adjuvant Treatment",
                        "BRAF V600-mutant Melanoma"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-15",
                "original_text": "Teva: ‘Hold’ Ratings from 55% of Analysts before 1Q18 Results",
                "features": {
                    "keywords": [
                        "Teva",
                        "Hold Ratings",
                        "Analysts",
                        "1Q18 Results"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-15",
                "original_text": "Analysts Raise Teva’s Earnings Estimates before Its 1Q18 Results",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Raise",
                        "Teva",
                        "Earnings Estimates",
                        "1Q18 Results"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-15",
                "original_text": "Could Teva Exceed Analysts’ Sales Estimates for 1Q18?",
                "features": {
                    "keywords": [
                        "Teva",
                        "Exceed",
                        "Analysts",
                        "Sales Estimates",
                        "1Q18"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "GlaxoSmithKline’s 1Q18 Earnings: Consumer Healthcare Business",
                "features": {
                    "keywords": [
                        "GlaxoSmithKline",
                        "1Q18 Earnings",
                        "Consumer Healthcare"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-25",
                "original_text": "The Swiss Stock Market Climbed On Roche Strength",
                "features": {
                    "keywords": [
                        "Swiss Stock Market",
                        "Climbed",
                        "Roche Strength"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}